Michael Aberman
General Partner at Regeneron Ventures
New York, New York
Overview
Work Experience
General Partner
2024 - Current
Board Member
2021
Stealth Biotech
Board Member
2020
Provide strategic, business development, and financing advice to CEO and CSO of UNP, an emerging biotech company that is unlocking the potential of macrocycle drug discovery through data science and massively parallel synthesis.
Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets.
Raised $38,000,000.00 from Human Ventures, Artis Ventures (AV), Merck Global Health Innovation Fund, The Venture Collective, LongeVC, Not Boring Capital, First Spark Ventures and Modi Ventures.
Business Advisor
2020 - 2024
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients. Pipeline projects include HIV, PML/JCV, HSV, and COVID-19 Treatment & Prevention. https://www.Excision.Bio/
Board Member
2020 - 2024
Rover Diagnostic’s Lightspeed is a potentially best-in-class, cost-effective, point-of-care, COVID-19 test that is saliva-based, CLIA-waived, and uses the gold-standard rtPCR to deliver results in under 15 minutes. It was accepted in the NIH RADx program to accelerate availability and capacity for COVID testing.
Columbia U biotech spin-out developing an ultrafast point of care molecular diagnostic test for COVID-19 and other infectious diseases.
SeniorAdvisor
2020 - 2022
Provide corporate strategy, business development, and financing advice to the CEO and CBO of Immunai, an innovate biotech company that is comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.
Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.
Raised $295,000,000.00 from Piedmont Capital Investments, Alexandria Venture Investments, Koch Disruptive Technologies, 8VC, ICon, Meron Capital and Talos VC.
President and CEO
2017 - 2019
Senior Vice President, Strategy and Investor Relations
2010 - 2017
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
Raised $15,931,980.00 from U.S. Department of Health & Human Services.
Biotech Analyst
2006 - 2010
Credit Suisse Group is a financial services company that advises clients in all aspects of finance.
Biotech Analyst
2004 - 2006
Morgan Stanley Venture Partners is a private equity firm that invests in high-growth companies in the technology and healthcare industries.